Skip to main content

Table 3 DenTiUS Deep Plaque clinical indices were obtained for test group A on day 4 (phase 1: receiving the cymenol mouthwash) and day 8 (phase 2: receiving the cymenol mouthwash)

From: Short-term anti-plaque effect of a cymenol mouthwash analysed using the DenTiUS Deep Plaque software: a randomised clinical trial

DenTiUS Deep Plaque clinical indices

Test group A

p-value

Phase 1_Day 4 (Mean % ± S.D.)

Phase 2_Day 8 (Mean % ± S.D.)

Visible plaque area (absolute)

35.31 ± 14.93

44.79 ± 15.77

0.001

Visible plaque area (relative)

29.80 ± 13.97

39.27 ± 14.33

0.001

Non-visible plaque area

27.69 ± 11.27

25.89 ± 10.37

0.262

Total plaque area

57.49 ± 13.26

65.17 ± 9.73

0.004*

Visible plaque area growth (absolute)

0.36 ± 0.15

0.23 ± 0.08

< 0.001

Visible plaque area growth (relative)

0.31 ± 0.14

0.20 ± 0.07

< 0.001

Total plaque area growth

0.60 ± 0.13

0.34 ± 0.05

< 0.001*

  1. Total plaque: visible plaque + non-visible plaque
  2. SD, standard deviation
  3. *Due to the non-normal distribution of some of the contrasted variables, the Wilcoxon test was applied to compare the two groups
Back to article page

BMC Oral Health

ISSN: 1472-6831

Contact us